Learn More About NIVESTYM

What is NIVESTYM?
NIVESTYM is a G-CSF (granulocyte colony-stimulating factor) biosimilar* to Neupogen.1†
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.
NIVESTYM does not have a designation of interchangeability with Neupogen.
 
NIVESTYM is FDA approved for all eligible indications of Neupogen in the following patient populations1:
PATIENTS WITH CANCER RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY
  • NIVESTYM is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING INDUCTION OR CONSOLIDATION CHEMOTHERAPY
  • NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
PATIENTS WITH CANCER UNDERGOING BONE MARROW TRANSPLANTATION
  • NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation
PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL COLLECTION AND THERAPY
  • NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
PATIENTS WITH SEVERE CHRONIC NEUTROPENIA
  • NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg, fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia